BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10201829)

  • 21. Structure-activity relationships of new NAPAP-analogs.
    Steinmetzer T; Schweinitz A; Künzel S; Wikström P; Hauptmann J; Stürzebecher J
    J Enzyme Inhib; 2001; 16(3):241-9. PubMed ID: 11697044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
    Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 24. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
    Supuran CT; Scozzafava A; Briganti F; Clare BW
    J Med Chem; 2000 May; 43(9):1793-806. PubMed ID: 10794696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological activity of dipeptides containing S-hexylcysteine.
    Bruzgo I; Midura-Nowaczek K
    Acta Pol Pharm; 2007; 64(5):479-82. PubMed ID: 18540170
    [No Abstract]   [Full Text] [Related]  

  • 26. Diamidino-alpha,omega-diphenoxyalkanes. Structure-activity relationships for the inhibition of thrombin, pancreatic kallikrein, and trypsin.
    Geratz JD; Whitmore AC
    J Med Chem; 1973 Sep; 16(9):970-5. PubMed ID: 4795664
    [No Abstract]   [Full Text] [Related]  

  • 27. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.
    Krishnan R; Zhang E; Hakansson K; Arni RK; Tulinsky A; Lim-Wilby MS; Levy OE; Semple JE; Brunck TK
    Biochemistry; 1998 Sep; 37(35):12094-103. PubMed ID: 9724521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position.
    Obreza A; Stegnar M; Urleb U
    Pharmazie; 2004 Sep; 59(9):659-67. PubMed ID: 15497744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
    Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of bovine beta-trypsin, human alpha-thrombin and porcine pancreatic beta-kallikrein-B by benzamidine and its bis-, tris- and tetra-derivatives: thermodynamic and molecular modeling study.
    Menegatti E; Ferroni R; Nastruzzi C; Bortolotti F; Scalia S; Amiconi G; Bolognesi M; Coletta M; Onesti S; Fruttero R
    Farmaco; 1991 Nov; 46(11):1297-310. PubMed ID: 1811616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombin inhibitor design.
    Sanderson PE; Naylor-Olsen AM
    Curr Med Chem; 1998 Aug; 5(4):289-304. PubMed ID: 9668196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
    Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
    Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
    Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors.
    Banner DW; Hadváry P
    J Biol Chem; 1991 Oct; 266(30):20085-93. PubMed ID: 1939071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor.
    Hauptmann J; Kaiser B; Paintz M; Markwardt F
    Pharmazie; 1989 Apr; 44(4):282-4. PubMed ID: 2772004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety.
    Lange UE; Baucke D; Hornberger W; Mack H; Seitz W; Höffken HW
    Bioorg Med Chem Lett; 2003 Jun; 13(12):2029-33. PubMed ID: 12781189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel plasma kallikrein inhibitors of the benzamidine type.
    Stürzebecher J; Prasa D; Wikström P; Vieweg H
    Braz J Med Biol Res; 1994 Aug; 27(8):1929-34. PubMed ID: 7749383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
    Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
    Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
    J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.